Ravindran Research Lab - Biomarkers

Ravindran Research Lab

About us | Physicians | Patients | Refer

Clinical Trials

Troriluzole

Diagnosis: OCD

Study: Addition of Troriluzole to usual treatment including antidepressant (10 week double-blind, placebo-controlled)

Patients with OCD often fail to respond adequately to pharmacotherapy, most usually SSRIs or SNRIs. This is a multicenter study designed to assess safety, tolerability, and efficacy of novel agent Troriluzole as adjunctive therapy when added to usual standard-of-care antidepressants. If eligible, participants can also enter directly into an open-label extension study for maintenance treatment up to 2 years.

Inclusion:

18-65 years old
Symptoms for at least a year
Failed response to current medications(SSRI, SNRI, or clomipramine)
Stable doses of other psychotropic medication for at least 3 months

Exclusion

Failed reponse (2 trials) to more than 2 previous treatment classes*
History of bipolar disorder, schizoaffective disorder or other psychotic disorder
Suicidality (past 12 months)
Subtance-use disorder
Use of stimulants, antipsychotics, mood stabilizers, and glatmatergic agents (4 weeks prior to study)

*For the purposes of this study, pharmacologic classes may be defined as including, but not limited to:

SSRIs and clomipramine (considered as one class)
SNRIs